After treatment with TPM-T1D, insulin-specific CD4+ T cells in the spleen not only increased in numbers but notably entailed a roughly 20% higher proportion of Tregs compared to TP treatment (Figures 5D–F). The gene discussed is CD4; the disease is type 1 diabetes mellitus.